| Species |
Human/Cynomolgus |
| Protein Construction |
Activin RIIA/ACVR2A (Ala20-Pro135)
Accession # P27037-1 (Human) / G7PKJ4 (Cynomolgus) |
mFc (IgG1) |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human Activin A, No Tag at 1μg/ml (100μl/well) on the plate can bind Activin RIIA/ACVR2A mFc Chimera, Human/Cynomolgus. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
39.07 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Activin A receptor type 2A (ACVR2A) is a membrane receptor in the transforming growth factor- beta (TGF-β signaling pathway, which is involved in the regulation of cell proliferation, migration, and apoptosis. Loss of ACVR2A has an important role in cancer progression and distant metastasis and may serve as a prognostic marker in patients with colon cancer. |
| Synonyms |
ACTR-IIA; ACTRIIA; ACVR2A; ACVR2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
